Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer

July 6, 2015

Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced that they have begun approving clinical trial centers for participation in its pivotal Phase 3 human clinical trial for Vicinium.

Click here f
or the full story.

Share This Story